Former FDA Official Advises on Best GMP practices During the Pandemic

Many of the guidance documents for drug developers and manufacturers that the FDA has issued during the COVID-19 pandemic are likely to continue to be in effect long after the public health emergency has passed, said Keith Webber, a former official in the FDA’s Center for Drug Evaluation and Research and the Center for Biologics Evaluation and Research.
Source: Drug GMP Report